Amendments to the Claims:

1. (Currently Amended) A formulation for the nasal absorption of insulin, which comprises a component composed of insulin and porous, spherical calcium carbonate as its carrier, said calcium carbonate having a relative surface area of 1.5 m^2/g or greater (BET method) and the porous, spherical calcium carbonate has a particle diameter substantially in the range of 20-32 μm, wherein the insulin is adsorbed or carried on said carrier as a monolayer or multilayer.

2. (Original) The formulation according to Claim 1, in which the porous, spherical calcium carbonate, comprises trabeculate or needle-shaped crystals, or an aggregation of the parallel intergrowth of these forms.

3-4. (Cancelled)

5. (Currently Amended) The formulation according to Claim 1, in which the porous, spherical calcium carbonate has a particle diameter substantially in the ~~substantial~~ range of 20-32 μm, and a median particle diameter of 22 μm or greater and less than 30 μm.

6. (Cancelled)

7. (Previously Amended) The formulation according to Claim 1, in which the insulin content of the component composed of insulin and porous, spherical calcium carbonate is 0.1-50% by weight based on the total weight of the component.

8. (Cancelled)

9. (Original) The formulation for the nasal absorption of insulin comprising a component composed of insulin and calcium carbonate as its carrier, in which the calcium carbonate is

substantially composed of cubic or trigonal system crystals and has a particle diameter in the range of 20-32 μm.

10. (Previously Amended) The formulation according to Claim 1, in which the insulin content of the component composed of insulin and calcium carbonate is 0.1-50% by weight based on the total weight of the component.

11. (Original) A method for the treatment of diabetes that comprises administering a component composed of insulin and porous, spherical calcium carbonate as its carrier into the nasal cavities of diabetics who need an effective amount of insulin.

12. (Original) The method according to Claim 11, in which the calcium carbonate is substantially composed of cubic or trigonal system crystals with a particle diameter in the range of 20-32 μm, and the insulin content of a combined component of insulin and calcium carbonate is 0.1-50% by weight based on the total weight of the component.

concld

13-14. (Cancelled)